Rostec aims to become leading drugmaker in Russia

24 April 2015

Rostec, a Russian state corporation which specializes on the development, production and export of hi-tech industrial products for civil and defense sectors, has announced its plans to become Russia’s largest producer of pharmaceuticals over the next several years, reports The Pharma Letter’s local correspondent.

As part of these plans, the National Immunobiological company (Natsimbio), has recently been established as a Rostec subsidiary, which is comprised of six leading Russian pharmaceutical enterprises.

Among these companies are Genfa, Synthesis, Fort, Biomedica and NGOs Microgen. The latter currently remains Russia's largest producer of immuno-biological products and one of the three largestpharmaceutical companiesinRussia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK